- Home
- About
- Resource Library
- Mental Health Disorders
- Agitation
- Anxiety Disorders
- Bipolar Disorder
- Cognition
- Depression
- Eating Disorders
- Personality Disorders
- PTSD/Trauma
- Schizophrenia
- Substance Use Disorders
- Women’s Health
- Topics of Interest
- Care Coordination
- Digital Health
- Diversity, Equity, & Inclusion
- Early Episode Psychosis
- Health Care Policy & Legislation
- Neuroscience
- Payer & Financing Models
- Quality Standards & Performance Measures
- Stigma
- Suicide Awareness
- Wellness
- Collections
- Featured
- Monthly Spotlight
- Psychopharmacology
- Learning Tracks
- Community Insights
- Community Podcast
- Disease Management & Support Tools
- Frameworks In Health & Quality Resources
- Mental Health System Guidebooks
- Patient & Caregiver Resource Center
- PsychU Roleplay
- Psychiatric Scales
- PsychUSim
- Events
Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder
Thank You For Attending Today’s Webinar
Please tell us what you thought about today’s presentation by taking the survey below:
About This Event
Long-Acting Injectable Antipsychotics & The Evolving Healthcare Landscape Post-COVID-19 Pandemic For Patients With Schizophrenia & Bipolar I Disorder
Schizophrenia and Bipolar Disorder have a significant burden that is expected to have escalated due to COVID-19. People with serious mental illness are at increased risk of COVID-19 and have higher rates of hospitalization, morbidity, and mortality. Drs. Correll and Chen will discuss how the pandemic has affected patients with schizophrenia and bipolar disorder, including access to long-acting injectable antipsychotics.
Moderator:
Gina Lau, PharmD
Regional Medical Lead, Otsuka Pharmaceutical Development & Commercialization, Inc.Featuring
-
Christoph Correll, MD
Professor of Psychiatry and Molecular Medicine; The Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Hempstead, NY; Professor and Chair; Department of Child and Adolescent Psychiatry, Psychosomatic Medicine and Psychotherapy; Charité University Medicine Berlin, Berlin, Germany
-
Maxine Chen , PhD
Director, U.S. Medical Affairs, Otsuka Pharmaceutical Development & Commercialization
-
Gina Lau, PharmD (OPDC)
Regional Medical Lead
Christoph Correll, MD is a paid consultant of Otsuka Pharmaceutical Development & Commercialization, Inc. Maxine Chen, PhD and Gina Lau, PharmD are employees of Otsuka Pharmaceutical Development & Commercialization, Inc.
Related Events
-
The Effects Of Racism On The Mental Healthcare Community: How Marginalized Patients & Providers Are Impacted
July 21 12:00 pm to 1:00 pm -
A Conversation With An Expert In Agitation In Alzheimer’s Dementia, A Person With Lived Experience, & A Care Partner
August 2 12:00 pm to 1:00 pm
Registration
Related Resources
-
Hot Topics: Clinical Questions In Bipolar Disorder (Part 5)
Interview July 4, 2022Drs. Mauricio Tohen and Joseph Goldberg will address current and relevant clinical questions relating to bipolar disorder. These questions and Dr. Tohen’s and Dr. Goldberg’s responses will be recorded and…
-
Culturally-Sensitive Assessments Of Trauma
Video July 1, 2022May is National Trauma Awareness Month and culturally-sensitive assessments of trauma is essential in providing proper support, validation and culturally informed care. In this recording, Dr. Sierra Carter discusses trauma…
-
Racial & Ethnic Diversity In Clinical Trials Infographic
Downloadable Resource June 30, 2022Download Infographic
Stay Connected:
- Resource Library